Abstract
ABSTRACT We report the formulation of nanoassemblies (NAs) comprising C225 conjugates Au-PFH-NAs (C-Au-PFH-NAs) for low-intensity focused ultrasound diagnosis ablation of thyroid cancer. C-Au-PFH-NAs showed excellent stability in water, phosphate-buffered saline (PBS), and 20% rat serum. Transmission electron microscopy (TEM) images also revealed the effective construction of C-Au-PFH-NAs as common spherical assemblies. The incubation of C625 thyroid carcinoma with C-Au-PFH-NAs triggers apoptosis, as confirmed by flow cytometry analysis. The C-Au-PFH-NAs exhibited antitumour efficacy in human thyroid carcinoma xenografts, where histopathological results further confirmed these outcomes. Furthermore, we were able to use low-intensity focused ultrasound diagnosis imaging (LIFUS) to examine the efficiency of C-Au-PFH-NAs in thyroid carcinoma in vivo. These findings clearly show that the use of LIFUS agents with high-performance imaging in different therapeutic settings will have extensive potential for future biomedical applications.
Highlights
Anaplastic thyroid carcinoma (ATC) is one of the most malignantcarcinomas
We demonstrate the self-assembly of C225 conjugate, Perfluorohexane/Gold Nanoparticles (Au-PFH-NPs), which results in low-intensity focused ultrasound diagnosis ablation of thyroid cancer treatment
We successfully examined the efficiency of C-Au-PFH-NPs when using the thyroid carcinoma low-intensity focused ultrasound (LIFUS) diagnostic imaging in vivo
Summary
Anaplastic thyroid carcinoma (ATC) is one of the most malignantcarcinomas. Low-intensity concentrated ultrasound (LIFUS) has beenexhaustively researched for tumor treatment along with the use ofultrasound imaging analysis as a potential exterior activate, whichis noninvasive and displays significant tissue-penetratingcapacity. It can significantly increase the efficacyof chemotherapy, avoiding harm to nearby cells, and reducingadversarial side effects [15]. The discharge ofLIFUS-triggered drugs from nanocarriers and further tumor therapyis still unsatisfactory. This is largely attributable to thecomparatively lower accumulation efficacy of nanoparticles-chargednano transporters at the tumor sites. Numerousnanotransporters have been extensively examined to enhance theaggregation of a large number of tumors without causing any sideeffects [15,16,17]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
